Myeloma News and Research

RSS

New study finds that serum miRNA profiles change as myeloma progresses

Virtually all patients who develop myeloma have an asymptomatic disease called monoclonal gammopathy of undetermined significance (MGUS) in the years before the onset of myeloma. The five-year relative survival rate for myeloma is 69% for patients diagnosed with stage I or localized disease, compared with 45% for patients with advanced cancer.

30 Sep 2015

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

Comparisons of cancer patients' survival and care in Europe up to 2007 show that although more patients are surviving for at least five years after diagnosis, there are large variations between countries, which are particularly significant in cancers of the blood.

26 Sep 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Protein-coding gene identified as tumor suppressor for acute myeloid leukemia

A protein-coding gene called hnRNP K has been identified as a tumor suppressor for acute myeloid leukemia (AML), a finding that could be important for investigating how best to target treatment of a blood cancer striking mostly older individuals.

24 Sep 2015

City of Hope receives gift to open new Judy and Bernard Briskin Center for Multiple Myeloma Research

The Judy and Bernard Briskin Family Foundation has announced a gift to launch the new Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope, the third named center within City of Hope's new Hematologic Malignancies and Stem Cell Transplantation Institute. The generous gift will enable the institution to further its already considerable accomplishments in the field of myeloma treatment and research.

24 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.

11 Sep 2015

Agent Orange exposure raises MGUS risk

The risk of monoclonal gammopathy of undetermined significance is significantly higher in individuals exposed than those not exposed to Agent Orange, shows a study of US Air Force personnel.

9 Sep 2015

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

The University of Pennsylvania's Abramson Cancer Center (ACC) has received an "exceptional" rating by the National Cancer Institute during an extensive peer-review process for its five-year competitive research support grant. The rating is the highest possible for an NCI cancer center.

9 Sep 2015

SKY92 genetic subtyping signature better than current markers in predicting progress of multiple myeloma

Article in Blood shows the reliability of SKY92 genetic subtyping signature for prediction of disease progress for multiple myeloma patient.

9 Sep 2015

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.

8 Sep 2015

Altering protein recycling complexes in human cells may help overcome chemotherapy resistance

Altering the protein recycling complexes in human cells, including cancer cells, allows the cells to resist treatment with a class of drugs known as proteasome inhibitors, according to Whitehead Institute scientists.

2 Sep 2015

BioLight Life Sciences Investments reports operational and financial results for Q2 2015

BioLight Life Sciences Investments, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the second quarter ended June 30, 2015.

1 Sep 2015

LLS, Light The Night National Corporate Partner Teams make positive impact on patients' lives

The Leukemia & Lymphoma Society is working with thousands of national partners, sponsors and corporate teams to fund lifesaving research and support for people battling cancer through the Light The Night Walk. Together with LLS, the Light The Night National Corporate Partner Teams are raising awareness and making a positive impact on the lives of patients today, literally, by taking steps to save lives.

28 Aug 2015

Continuous therapy improves multiple myeloma outcomes

Patients with newly diagnosed multiple myeloma receive significant progression-free and overall survival benefits from continuous treatment compared with fixed-duration therapy, suggests a pooled analysis.

27 Aug 2015

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

Kidney Cancer is among the 10 most diagnosed cancers in both men and women in the United States, and it is estimated that more than 60,000 new cases of kidney cancer will be diagnosed in 2015.

27 Aug 2015

Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.

27 Aug 2015

Leukemia & Lymphoma Society to kick off 2015 Light The Night Walk campaign throughout Northern California

The Leukemia & Lymphoma Society will be kicking off its 2015 Light The Night Walk campaign throughout Northern California with the Napa Valley Walk on September 26, 2015 at 5 p.m. PT at Veterans Memorial Park.

25 Aug 2015

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

Myeloma News and Research

New study finds that serum miRNA profiles change as myeloma progresses

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Protein-coding gene identified as tumor suppressor for acute myeloid leukemia

City of Hope receives gift to open new Judy and Bernard Briskin Center for Multiple Myeloma Research

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Agent Orange exposure raises MGUS risk

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

SKY92 genetic subtyping signature better than current markers in predicting progress of multiple myeloma

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Altering protein recycling complexes in human cells may help overcome chemotherapy resistance

BioLight Life Sciences Investments reports operational and financial results for Q2 2015

LLS, Light The Night National Corporate Partner Teams make positive impact on patients' lives

Continuous therapy improves multiple myeloma outcomes

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

Leukemia & Lymphoma Society to kick off 2015 Light The Night Walk campaign throughout Northern California

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News